Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 5/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | NOS2 | P35228 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | TNF | P01375 | 3/20 | 0.40 |
| ▸ | NOD2 | Q9HC29 | 2/20 | 0.40 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.40 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.40 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.40 |
| ▸ | GALR3 | O60755 | 1/20 | 0.40 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | TYMS | P04818 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1053419 | 0.77 | SMN1; SMN2 (1.00) | SMN1; SMN2LMNARAB9AKDM4EMEN1 | |
| SCHEMBL7394357 | 0.77 | SMN1; SMN2 (0.52) | SMN1; SMN2LMNARAB9AKDM4EMEN1 | |
| SCHEMBL2885907 | 0.76 | HTT (0.55) | SMN1; SMN2LMNARAB9AKDM4ENPC1 | |
| SCHEMBL8956416 | 0.76 | SMN1; SMN2 (0.61) | SMN1; SMN2LMNATDP1NOS2RAB9A | |
| SCHEMBL4027582 | 0.76 | SMN1; SMN2 (0.61) | SMN1; SMN2LMNATDP1NOS2RAB9A | |
| SCHEMBL9739302 | 0.74 | LMNA (0.42) | SMN1; SMN2LMNARAB9AKDM4EMEN1 | |
| SCHEMBL6733842 | 0.74 | SMN1; SMN2 (0.53) | SMN1; SMN2LMNARAB9AKDM4EMEN1 | |
| SCHEMBL6589381 | 0.72 | SMN1; SMN2 (0.56) | SMN1; SMN2LMNARAB9AKDM4EMEN1 | |
| SCHEMBL3373218 | 0.72 | SMN1; SMN2 (0.42) | SMN1; SMN2LMNANOS2KDM4EMEN1 | |
| SCHEMBL31759194 | 0.72 | SMN1; SMN2 (0.74) | SMN1; SMN2LMNARAB9AKDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 360 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118126467-A | Heat-resistant modified polyvinyl chloride power tube and preparation method thereof | 杭州鼎新建科实业有限公司 | 2024-06-04 | — | — | CN | claimed |
| CN-111335033-A | Neckerchief fabric for infant care and preparation method thereof | 张海军 | 2020-06-26 | — | — | CN | claimed |
| US-8188254-B2 | C-class oligonucleotide analogs with enhanced immunostimulatory potency | COLEY PHARMACEUTICAL GMBH (DE) | 2012-05-29 | — | — | US | claimed |
| EP-1978997-A1 | TRANSDERMAL DELIVERY OF PHARMACEUTICAL AGENTS | Apollo Life Sciences Limited (AU) | 2008-10-15 | — | — | EP | claimed |
| EP-1861387-A1 | NOVEL BENZOIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2007-12-05 | — | — | EP | claimed |
| WO-2007070983-A1 | TRANSDERMAL DELIVERY OF PHARMACEUTICAL AGENTS | APOLLO LIFE SCIENCES LIMITED (AU) | 2007-06-28 | — | — | WO | claimed |
| EP-1730281-A2 | IMMUNOSTIMULATORY NUCLEIC ACIDS FOR INDUCING IL-10 RESPONSES | Coley Pharmaceutical Group, Inc. (US) | 2006-12-13 | — | — | EP | claimed |
| EP-1728863-A2 | C-class oligonucleotide analogs with enhanced immunostimulatory potency | Coley Pharmaceutical GmbH (DE) | 2006-12-06 | — | — | EP | claimed |
| WO-2006080821-A1 | NOVEL BENZOIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2006-08-03 | — | — | WO | claimed |
| EP-1678303-A2 | C-CLASS OLIGONUCLEOTIDE ANALOGS WITH ENHANCED IMMUNOSTIMULATORY POTENCY | Coley Pharmaceutical GmbH (DE) | 2006-07-12 | — | — | EP | claimed |
| WO-2005111057-A2 | IMMUNOSTIMULATORY NUCLEIC ACIDS FOR INDUCING IL-10 RESPONSES | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2005-11-24 | — | — | WO | claimed |
| US-20050239734-A1 | C-class oligonucleotide analogs with enhanced immunostimulatory potency | COLEY PHARMACEUTICAL GMBH (DE) | 2005-10-27 | — | — | US | claimed |
| EP-1578954-A2 | 5' CPG NUCLEIC ACIDS AND METHODS OF USE | Coley Pharmaceutical Group, Inc. (US) | 2005-09-28 | — | — | EP | claimed |
| WO-2005042018-A2 | C-CLASS OLIGONUCLEOTIDE ANALOGS WITH ENHANCED IMMUNOSTIMULATORY POTENCY | COLEY PHARMACEUTICAL GMBH (DE) | 2005-05-12 | — | — | WO | claimed |
| US-20040171571-A1 | 5' CpG nucleic acids and methods of use | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2004-09-02 | — | — | US | claimed |
| WO-2004053104-A2 | 5’ CPG NUCLEIC ACIDS AND METHODS OF USE | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2004-06-24 | — | — | WO | claimed |
| US-12637646-B2 | DNA origami cell sensing platform | OHIO STATE INNOVATION FOUNDATION (US) | 2026-05-26 | — | — | US | disclosed |
| US-20260139247-A1 | ENGINEERED ENVELOPED VECTORS AND METHODS OF USE THEREOF | GIGAMUNE INC (US) | 2026-05-21 | — | — | US | disclosed |
| WO-2004005476-A2 | NUCLEIC ACID COMPOSITIONS FOR STIMULATING IMMUNE RESPONSES | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2004-01-15 | — | — | WO | disclosed |
| US-4594420-A | Substituted with bromine or chlorine | HOECHST AKTIENGESELLSCHAFT (DE) | 1986-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260139247-A1 | ENGINEERED ENVELOPED VECTORS AND METHODS OF USE THEREOF | TMIGD3, TMPRSS11D, TMED2 | SMN1; SMN2 213/4885LMNA 1104/4885TDP1 1295/4885 |
| US-12637646-B2 | DNA origami cell sensing platform | DNMT3A, EPCAM, CASR | SMN1; SMN2 1592/4885LMNA 197/4885TDP1 203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.